• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Accuray Incorporated

    5/22/26 3:57:32 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care
    Get the next $ARAY alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)


    Accuray Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    004397105

    (CUSIP Number)
    Andrew Bowden
    515 S. Flower Street,
    Los Angeles, CA, 90071
    213-244-0731

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    05/19/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    schemaVersion:


    SCHEDULE 13D

    CUSIP Number(s):
    004397105


    1 Name of reporting person

    The TCW Group, Inc., on behalf of the TCW Business Unit
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NEVADA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    18,942,059.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    18,942,059.00
    11Aggregate amount beneficially owned by each reporting person

    18,942,059.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    13.7 %
    14Type of Reporting Person (See Instructions)

    CO, HC

    Comment for Type of Reporting Person:
    Row 13. The calculation of the percentage of beneficial ownership is based on (i) 118,963,696 shares of Common Stock (as defined below) outstanding as of May 19, 2026 as disclosed by the Issuer to the TCW Business Unit, plus (ii) 18,942,059 shares of Common Stock issuable upon exercise of the Warrants (as defined below).


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock
    (b)Name of Issuer:

    Accuray Inc
    (c)Address of Issuer's Principal Executive Offices:

    1240 Deming Way, Madison, WISCONSIN , 53717.
    Item 1 Comment:
    This Amendment No. 2 (this "Amendment No.2") amends and supplements the statement on Schedule 13D (the "Original Schedule 13D") filed by The TCW Group, Inc. ("TCW") on behalf of itself and its direct and indirect subsidiaries, on June 17, 2025, as amended by Amendment No. 1 to Schedule 13D filed on April 17, 2026, ("Amendment No. 1," and together with the Original Schedule 13D, the "Schedule 13D"), relating to the Common Stock, par value $0.001 per share (the "Common Stock"), of Accuray Incorporated, a Delaware corporation (the "Issuer").
    Item 2.Identity and Background
    (a)
    N/A
    (b)
    N/A
    (c)
    N/A
    (d)
    N/A
    (e)
    N/A
    (f)
    N/A
    Item 3.Source and Amount of Funds or Other Consideration
     
    The disclosure in Item 3 is supplemented by adding the following: On May 19, 2026, the Issuer issued (x) to TCW Rescue Financing and TCW Direct Lending, respectively, (x) Common Stock Purchase Warrants to purchase 1,010,028 shares and 75,630 shares, respectively, of Common Stock at an exercise price of $1.25 per share (the "May Premium Warrants"), (y) Common Stock Purchase Warrants to purchase 1,414,040 shares and 105,882 shares, respectively, of Common Stock at an exercise price of $1.50 per share (the "May Super Premium Warrants"), in each case of the May Premium Warrants and Super Premium Warrants, exercisable on and after six months and one day after May 19, 2026 and expiring on May 19, 2033, and (z) Common Stock Purchase Warrants to purchase 808,023 shares and 60,504 shares, respectively, of Common Stock at an exercise price of $0.01 per share (the "December Penny Warrants"), exercisable on and after May 19, 2026 and expiring on May 19, 2033 (the May Premium Warrants, May Super Premium Warrants and May Penny Warrants, collectively, the "May Warrants" and, together with the June Warrants and December Warrants, the "Warrants").The May Warrants were issued to the holders thereof in connection with the making of a Delayed Draw Term Loan (as defined in the Financing Agreement) by the Issuer. Pursuant to the terms of the Financing Agreement, the issuance of the May Warrants was a condition to the obligations of the lenders under the Financing Agreement making such Delayed Draw Term Loan. No separate consideration was paid by the holders thereof for such May Warrants, and no exercise of the May Warrants has occurred. Any separate exercise price under the Warrants, if applicable, would be paid using working capital funds.
    Item 4.Purpose of Transaction
     
    The disclosure in Item 4 is supplemented by adding the following: The May Warrants were issued as consideration for, and as a condition to, the lenders under the Financing Agreement providing the Delayed Draw Term Loan (as defined in the Financing Agreement).
    Item 5.Interest in Securities of the Issuer
    (a)
    The percentages of beneficial ownership reported in this Item 5, and on the cover page to this Amendment No.2, are based on (i) 118,963,696 shares of Common Stock (as defined below) outstanding as of May 19, 2026 as disclosed by the Issuer to the TCW Business Unit, plus (ii) 18,942,059 shares of Common Stock issuable upon exercise of the Warrants. The cover page to this Amendment No. 2 is incorporated by reference in its entirety into this Item 5(a, b). The TCW Business Unit holds, and thus has shared voting and dispositive power over, 18,942,059 shares of Common Stock of the Issuer (which is equal to approximately 13.7% of the number of the Issuer's issued and outstanding shares of Common Stock, including shares of Common Stock issuable upon exercise of the Warrants) through ownership of the Warrants issued by the Issuer to TCW Rescue Financing and TCW Direct Lending.
    (b)
    [to be combined with Item 5(a) directly above]
    (c)
    Other than as set forth in Item 3 above and the acquisition of the December Warrants described in Amendment No. 1, the reporting person has not effected any transaction involving shares of Common Stock during the 60 days prior to the filing of this Schedule 13D.
    (d)
    No person other than the reporting person is known to have the right to receive or the power to direct receipt of dividends from, or the proceeds from the sale of, the Warrants.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    The disclosure in Item 6 is supplemented by adding the following: The responses in Items 3 of this Amendment No.2 are incorporated herein by reference in their entirety.
    Item 7.Material to be Filed as Exhibits.
     
    The disclosure in Item 7 is supplemented by adding the following: Exhibit 13 - Common Stock Purchase Warrant, dated as of May 19, 2026, by and between TCW Rescue Financing and the Issuer (the TCW Rescue Financing May Premium Warrant). Exhibit 14 - Common Stock Purchase Warrant, dated as of May 19, 2026, by and between TCW Direct Lending and the Issuer (the TCW Direct Lending May Premium Warrant). Exhibit 15 - Common Stock Purchase Warrant, dated as of May 19, 2026, by and between TCW Rescue Financing and the Issuer (the TCW Rescue Financing May Super Premium Warrant). Exhibit 16 - Common Stock Purchase Warrant, dated as of May 19, 2026, by and between TCW Direct Lending and the Issuer (the TCW Direct Lending May Super Premium Warrant). Exhibit 17 - Common Stock Purchase Warrant, dated as of May 19, 2026, by and between TCW Rescue Financing and the Issuer (the TCW Rescue Financing May Penny Warrant). Exhibit 18 - Common Stock Purchase Warrant, dated as of May 19, 2026, by and between TCW Direct Lending and the Issuer (the TCW Direct Lending May Penny Warrant).

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The TCW Group, Inc., on behalf of the TCW Business Unit
     
    Signature:/s/ Andrew Bowden
    Name/Title:Andrew Bowden, Executive Vice President
    Date:05/22/2026
    Get the next $ARAY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARAY

    DatePrice TargetRatingAnalyst
    5/7/2026Buy → Neutral
    BTIG Research
    2/13/2024$9.00Buy
    ROTH MKM
    6/23/2022$7.50Buy
    B. Riley Securities
    12/22/2021$7.50Buy
    Loop Capital
    More analyst ratings

    $ARAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Accuray downgraded by BTIG Research

    BTIG Research downgraded Accuray from Buy to Neutral

    5/7/26 8:01:20 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    ROTH MKM initiated coverage on Accuray with a new price target

    ROTH MKM initiated coverage of Accuray with a rating of Buy and set a new price target of $9.00

    2/13/24 6:29:42 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    B. Riley Securities initiated coverage on Accuray with a new price target

    B. Riley Securities initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

    6/23/22 7:25:39 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    SEC Filings

    View All

    SEC Form SD filed by Accuray Incorporated

    SD - ACCURAY INC (0001138723) (Filer)

    5/29/26 4:10:26 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Accuray Incorporated

    S-8 - ACCURAY INC (0001138723) (Filer)

    5/29/26 4:01:37 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Accuray Incorporated

    SCHEDULE 13D/A - ACCURAY INC (0001138723) (Subject)

    5/22/26 3:57:32 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mayer Steven F bought $30,878 worth of shares (54,875 units at $0.56), increasing direct ownership by 4% to 1,545,620 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    2/23/26 4:10:08 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Director Mayer Steven F bought $103,797 worth of shares (195,125 units at $0.53), increasing direct ownership by 15% to 1,490,745 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    2/20/26 4:10:06 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    CEO La Neve Stephen R. bought $19,410 worth of shares (20,000 units at $0.97) (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    11/19/25 5:18:33 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules

    MADISON, Wis., May 29, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Paul Miele, the company's new Chief Commercial Officer and David Shin, the company's new Chief Legal Officer. As material inducements to Mr. Miele and Mr. Shin joining the company, and in accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee approved the granting of equity inducement awards to each of Mr. Miele and Mr. Shin, in each case effective as of May 29, 2026 (collectively, the "Inducement Awar

    5/29/26 4:10:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with Cancer

    MADISON, Wis., May 15, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) announced a new 10‑year strategic collaboration to advance personalized cancer treatments using Accuray's Stellar™ adaptive radiation therapy platform. This agreement builds on longstanding shared history of partnership between Accuray and the school to develop precision radiation therapy technologies using imaging to precisely deliver dose sculpting for cancer treatments. This newest collaboration will support clinical research, education and training, and the development of adaptive therapies that help empower medical care teams to co

    5/15/26 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026

    MADISON, Wis., April 22, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the third quarter of fiscal year 2026, ended March 31, 2026, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on May 6, 2026. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (international), c

    4/22/26 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by SVP, Chief Commercial Officer Miele Paul Michael

    4 - ACCURAY INC (0001138723) (Issuer)

    5/29/26 7:29:02 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Large owner Tcw Group Inc

    4 - ACCURAY INC (0001138723) (Issuer)

    5/21/26 9:03:07 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Tcw Group Inc

    3 - ACCURAY INC (0001138723) (Issuer)

    4/17/26 6:01:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Leadership Updates

    Live Leadership Updates

    View All

    Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer

    MADISON, Wis., April 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele will join Accuray's executive leadership team and lead the company's global commercial organization as Accuray continues to advance its transformation and strengthen execution across its portfolio. "Paul brings deep global commercial leadership experience and a strong track record of driving transform

    4/6/26 9:00:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray Accelerates Transformation Efforts with Appointment of Experienced Executive Leaders to Drive Performance and Growth

    Industry Veteran Steve La Neve Named Chief Executive Officer Suzanne Winter to Retire as President and CEOCompany Appoints Steven F. Mayer as Transformation Board SponsorChan W. Galbato Nominated to Board of Directors MADISON, Wis., Oct. 20, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today announced it is engaging in a significant organizational, strategic, and operational transformation. To accelerate this work, the company's Board of Directors has appointed proven industry leaders with deep operational expertise to drive execution, strengthen performance, and enhance competitiveness. The transformation plan initiatives, most of which will be implemented during the current fisc

    10/20/25 9:20:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

    6/30/25 11:02:00 AM ET
    $ARAY
    $CLRB
    $ERAS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ARAY
    Financials

    Live finance-specific insights

    View All

    Accuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026

    MADISON, Wis., April 22, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the third quarter of fiscal year 2026, ended March 31, 2026, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on May 6, 2026. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (international), c

    4/22/26 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray Reports Fiscal 2026 Second Quarter Financial Results

    MADISON, Wis., Feb. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the second quarter ended December 31, 2025. Key Highlights  On December 15, 2025 the Company announced the first phase of comprehensive, strategic, operational, and organizational transformational plan, which is expected to improve annualized operating profitability by approximately $25 million and set the stage for revenue growth:Plan includes organizational realignment, rightsizing of cost structure, outsourcing, and sales enablement in order to enhance competi

    2/4/26 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026

    MADISON, Wis., Jan. 21, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the second quarter of fiscal year 2026, ended December 31, 2025, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on February 4, 2026. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (interna

    1/21/26 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Accuray Incorporated

    SC 13G/A - ACCURAY INC (0001138723) (Subject)

    9/6/24 9:00:07 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Accuray Incorporated

    SC 13G - ACCURAY INC (0001138723) (Subject)

    2/13/24 4:56:01 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Accuray Incorporated (Amendment)

    SC 13G/A - ACCURAY INC (0001138723) (Subject)

    2/13/24 11:19:22 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care